Aardvark Therapeutics, Inc. (AARD)
Health Care · biotechnology · NASDAQ
Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule treatments for metabolic diseases and Prader-Willi Syndrome.
What Aardvark Therapeutics, Inc. does
Aardvark Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small-molecule therapeutics to activate innate homeostatic pathways. Its primary development efforts are targeted at metabolic diseases and hunger-associated conditions, specifically Prader-Willi Syndrome (PWS). The company currently has no products approved for commercial sale and is in the process of evaluating clinical data for its lead candidate.
Recent developments
In May 2026, the FDA placed a full clinical hold on the ARD-101 IND, leading the company to terminate its Phase 3 HERO and OLE trials in June 2026. Management is currently assessing unblinded clinical data from these trials to determine next steps while maintaining active discussions with the FDA.
From Aardvark Therapeutics, Inc.'s filing of 2026-08-11.
Themes: metabolic diseases, Prader-Willi Syndrome (PWS), hunger regulation therapeutics, small-molecule drugs
Fundamentals
- Price$3.90 as of 2026-10-20 close
- Market cap$85M as of 2026-07-31 (share count; price 2026-10-20)
- 1-year return-68.2% 2025-10-20 close $12.28 → 2026-10-20 close $3.90
- P/En/a negative earnings
- ROE-54.0% FY2025, SEC XBRL
- ROICn/a No figure: its 10-K tags no pre-tax income, so no tax rate can be taken.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Beta1.93 as of 2026-09-03
- Last reported earnings2026-08-11 SEC EDGAR Form 8-K (Item 2.02)
How AARD compares in its sector
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | -$15M | -$14M | -$0.66 | -$18M† | — |
| Q1 FY2026 2026-03-31 | -$22M | -$22M | -$0.99 | -$19M | — |
| Q4 FY2025 2025-12-31 | -$19M† | -$18M† | -$0.81† | -$17M† | $0† |
| Q3 FY2025 2025-09-30 | -$18M | -$16M | -$0.75 | -$16M† | $4000† |
| Q2 FY2025 2025-06-30 | -$16M | -$14M | -$0.66 | -$10M† | $91000† |
| Q1 FY2025 2025-03-31 | -$10M | -$9M | -$0.71 | -$11M | $0 |
| Q4 FY2024 2024-12-31 | -$9M† | -$9M† | -$2.18† | -$8M† | $6000† |
| Q3 FY2024 2024-09-30 | -$5M | -$4M | -$1.05 | -$4M† | $5000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$74M
- Short-term investments$21000
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How Aardvark Therapeutics, Inc. looks technically
Aardvark Therapeutics, Inc. (AARD) is trading 46.6% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 142 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 28, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 32, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 10 trading days ago (its momentum flipped negative). It made a new 20-day low about 2 trading days ago. It is 78.3% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 46.6% below its 200-day average, the long-term trend line — a long-term downtrend | -46.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $5.49 | $5.49 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $7.30 | $7.30 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 28 calendar days ago — the swings before that are what the structure reading is measured on | 28 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 5.84. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 142 trading days ago — a "death cross", a bearish long-term signal | 142 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 28, with sellers in control | 27.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 32, neither overbought (above 70) nor oversold (below 30) | 32.3 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($3.64 to $5.66) — its "stochastic" reading is 13 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 12.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 10 trading days ago (its momentum flipped negative) | 10 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $17.94 | $17.94 |
|---|---|---|
| From the 52-week high | it is 78.3% below its 52-week high (its highest price of the past year) | -78.3% |
| Above the 52-week low | it is 16.4% above its 52-week low (its lowest price of the past year) | +16.4% |
| Below the 52-week high | it is 78.3% below its highest point of the past year | 78.3% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day low about 2 trading days ago | 2 sessions |
| All-time high | its highest closing price on record is $19.58 (set on 2025-02-20) | $19.58 |
| Given back of the 52-week move | over the past year its closes ranged ($3.48 to $17.41), and it has recovered only a small part of its fall from last year’s high — 3% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $12.09 to $12.53. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 3.0% |
| From the all-time high | it is 80.1% below its all-time high | -80.1% |
| Nearest price level | it is trading 13.5% above a support level at $3.38 — a price it turned at twice since 2026-03-27, most recently on 2026-06-11. Since 2025-02-13 it has 1 such level below the current price and 10 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -13.5% |
| All-time low | its lowest closing price on record is $3.35 (set on 2026-03-27) | $3.35 |
| Above the all-time low | it is 16.4% above its all-time low | +16.4% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 68th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.4814 between its high and its low — about 12.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.4814 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.48 and $5.98 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.48 – $4.73 – $5.98 |
| Typical daily range (% of price) | its price moves about 12.3% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 12.3% |
| Stretch from the 200-day average | it is trading 7.1 daily ranges below its 200-day average price (46.6% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 7.1 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.50× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has improved toward "buy" since the prior reading | 0.07 toward buy |
Candlestick patterns
2
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-20 1.6% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +1.6% |
|---|---|---|
| Open gap | it gapped 2.3% below the previous close 36 sessions ago and has not traded back through the level it left behind at 6.62 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -2.3% |
| Gap filled | a 8.6% gap up opened on 2026-10-16 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 2 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 28.5 percentage points (the stock lost 27.5% while the market gained 1.0%) | -28.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 33.1 percentage points (the stock lost 29.5% while the market gained 3.6%) | -33.1% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 39.5 percentage points (the stock lost 31.0% while the market gained 8.5%) | -39.5% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 82.8 percentage points (the stock lost 68.2% while the market gained 14.6%) | -82.8% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 33% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 12.0% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -33.5% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 41% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $6.59 — a volume-weighted average of daily closes over 191 sessions, not a true tick-by-tick VWAP. | -40.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 29% below the average price paid since it last reported on 2026-08-11 (its 10-Q), so the typical buyer over that stretch is under water. That average is $5.49 — a volume-weighted average of daily closes over 50 sessions, not a true tick-by-tick VWAP. | -28.9% |
Price levels it has turned at before
AARD last closed at $3.90 on 2026-10-20. Since 2025-02-13 it has turned at 1 price below its last close and 10 above; the nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $3.38 | Support | 13.5% below the last close | turned there twice · 2026-03-27 to 2026-06-11 |
| $4.71 | Resistance | 20.9% above the last close | turned there twice · 2026-03-03 to 2026-07-09 |
| $4.88 | Resistance | 25.1% above the last close | turned there twice · 2025-04-09 to 2026-04-29 |
| $5.33 | Resistance | 36.5% above the last close | turned there twice · 2026-07-21 to 2026-07-29 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $5.84.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $1.36 and $3.07 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $5.84.
This reading has stood for 16 trading days, since 2026-09-29.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · lagging the market · Just filled a gap (5%+ closed in the last week) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.18 mean, 1=Strong Buy…5=Strong Sell) — 9 analysts
- Mean price target$11.11 range $3.00 – $28.00; median $6.00
Analyst estimates, as of 2026-10-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for AARD
- Consensus EPS estimate-$0.7475 next reporting period, as of 2026-10-17
- Estimate change, 30 days+$0.02472 from -$0.7722, on 2026-09-17, 30-day window
- Readings revised upward22% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Heavy dependence on the successful development and regulatory approval of the lead candidate, ARD-101.","The FDA has placed a full clinical hold on the ARD-101 IND, which has resulted in the termination of ongoing Phase 3 trials.","History of significant operating losses and the requirement for substantial additional financing to continue operations beyond late 2027."]
What changed in the latest 10-Q
AI-assisted comparison of AARD's 10-Q filed 2026-08-11 against the prior one filed 2026-05-07.
Risk Factors
- Added:
- Newer filing (2026-08-11) adds the words "projects, initiatives," to the summary bullet: "fail to capitalize on projects, initiatives, product candidates or indications that may be more profitable or for which there is a greater likelihood of success."
- Removed:
- Older filing (2026-05-07) ends with the text "*We have incurred significant losses since our inception and expect to incur losses over the next several years and may never achieve or maintain profitability." This text is truncated in the newer filing where the section ends with "...may never achieve or maintain profitabili".
- Reworded:
- Older filing (2026-05-07) summary bullet reads: "fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success." Newer filing (2026-08-11) reads: "fail to capitalize on projects, initiatives, product candidates or indications that may be more profitable or for which there is a greater likelihood of success."
- Notes:
- The newer filing text is truncated at the end ("...may never achieve or maintain profitabili"), so changes after that point cannot be compared.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 2 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 90 days · read to 2026-10-160 buys · 2 sells ($394957) — 1 selling insider
- Last 180 days · read to 2026-10-160 buys · 2 sells ($394957) — 1 selling insider
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-11. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about AARD's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding AARD as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 2,949,754
- Reported value $16,990,583
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 2 increased, 2 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about AARD's institutional holders → See what each manager we track holds →
Short interest (FINRA)
AARD had 474,080 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
AARD had 2.17% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.29 days to cover at the same settlement.
- Reported short interest (shares) 474,080
- Short interest (% of shares outstanding) 2.17%
- Prior settlement (shares) 424,912
- Reported change 11.57%
- Days to cover (reported) 5.29
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Rhythm Pharmaceuticals (RYTM)
- Concordia Pharmaceuticals
- Soleno Therapeutics (SLNO)
- Radius Health
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare AARD vs…
Frequently asked questions
What does Aardvark Therapeutics, Inc. (AARD) do?
Aardvark Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small-molecule therapeutics to activate innate homeostatic pathways. Its primary development efforts are targeted at metabolic diseases and hunger-associated conditions, specifically Prader-Willi Syndrome (PWS). The company currently has no products approved for commercial sale and is in the process of evaluating clinical data for its lead candidate.
What sector is Aardvark Therapeutics, Inc. (AARD) in?
Aardvark Therapeutics, Inc. (AARD) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are Aardvark Therapeutics, Inc.'s (AARD) competitors?
Notable peers of Aardvark Therapeutics, Inc. (AARD) include Rhythm Pharmaceuticals, Concordia Pharmaceuticals, Soleno Therapeutics and Radius Health. This peer set is informational only — not financial advice.
Is Aardvark Therapeutics, Inc. (AARD) overbought or oversold right now?
Aardvark Therapeutics, Inc. (AARD) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 32, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AARD come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.